1Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes [J]. Blood, 1995,86 :268-276.
2Aizawa S, Nakano M, lwase O, et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34^+ positive cell proliferation and differentiation in vitro[J]. Leuk Res, 1999,23,239- 246.
3Rajapaksa R, Ginzton N, Rott L,et al. Altered oneoprotein expression and apoptosis in myelodysplastic syndrome marrow cells[J]. Blood, 1996, 88: 4275- 4287.
4Sherry V, Mundle S, Alvi S,et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes [J]. Leuk Res, 1996,20:891- 900.
5Bouscary D, Chen Y L, Guesnu M,et al. Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro[J]. Exp Hematol, 2000, 28: 784 -791.
6Ribizzi I. Darnowski J W, Goulette F A,et al. Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line[J]. Leuk Res, 2000,24 (6) : 519- 525.
7Yilmaz A, Kaufmann C C, Binder C,et al. Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome [J]. Ann Hematol, 2001, 80(1):53-57.
8Invernizzi R. Pecci A. Travaglino E.et al. Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes [J]. Br J Haematol. 2002.118(I) :246- 250,.
9Raza A. Qawi H, Andric T. et al. Pentoxifylline, Ciprofloxacin and Dexamethasone improve the ineffective hematopolesls in myelodysplastlc syndrome patients [J]. Malignancy Hematol, 2000,5 (4) : 275 - 284.
10Gersuk G M, Beckham C, Loken M R, et al. A role for tumor necrosis factora. Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome[J]. Br J Haematol,1998,103:176-188.
